Open-Label Extension of Other SZ1839 (Iressa) Trials
Phase 3
Completed
- Conditions
- Cancer
- Registration Number
- NCT00635973
- Lead Sponsor
- AstraZeneca
- Brief Summary
A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Received treatment in a previous Iressa clinical trial
- Provided Informed Consent to participate in the trial
- 30 days or less since completing the previous Iressa trial.
Read More
Exclusion Criteria
- Radiotherapy completed more than 14 days before starting treatment in this trial
- Incomplete healing from prior surgery
- Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Adverse Events Every 28 days
- Secondary Outcome Measures
Name Time Method Progression Free Survival Every 28 days Survival Every 28 days